Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Spyre Therapeutics, Inc.
13D/A
SYRE · 00773J202
|
10.0% |
10/9/2026
Event 10/7/2026
|
|||
| Fairmount Funds Management LLC | 9.2% | ||||
| Fairmount Healthcare Fund II L.P. | 9.2% | ||||
| Harwin Peter Evan | 10.0% | ||||
| Kiselak Tomas | 10.0% | ||||
|
Korsana Biosciences, Inc.
13D
KRSA · 23255M303
|
20.0% |
9/11/2026
Event 9/8/2026
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 15.2% | ||||
| Fairmount Healthcare Co-Invest VI L.P. | 4.8% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Apogee Therapeutics, Inc.
13D/A
APGE · 03770N101
|
0% |
9/3/2026
Event 9/3/2026
|
|||
| Fairmount Funds Management LLC | 0% | ||||
| Fairmount Healthcare Fund II L.P. | 0% | ||||
| Peter Evan Harwin | 0% | ||||
| Tomas Kiselak | 0% | ||||
|
Crescent Biopharma, Inc.
13D/A
CBIO · G2545C104
|
16.5% |
7/20/2026
Event 7/16/2026
|
|||
| Fairmount Funds Management LLC | 16.5% | ||||
| Fairmount Healthcare Fund II L.P. | 16.5% | ||||
| Peter Harwin | 16.5% | ||||
| Tomas Kiselak | 16.5% | ||||
|
Oruka Therapeutics, Inc.
13D/A
ORKA · 687604108
|
19.5% |
7/1/2026
Event 7/1/2026
|
|||
| Fairmount Funds Management LLC | 19.5% | ||||
| Fairmount Healthcare Fund II L.P. | 16.0% | ||||
| Fairmount Healthcare Co-Invest III L.P. | 4.0% | ||||
| Harwin Peter Evan | 19.5% | ||||
| Kiselak Tomas | 19.5% | ||||
|
Jade Biosciences, Inc.
13D/A
JBIO · 008064206
|
20.0% |
6/9/2026
Event 6/5/2026
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 16.2% | ||||
| Fairmount Healthcare Co-Invest IV L.P. | 4.4% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Enliven Therapeutics, Inc.
13G/A
ELVN · 29337E102
|
3.1% |
5/15/2026
Event 3/31/2026
|
|||
| Fairmount Funds Management LLC | 3.1% | ||||
| Fairmount Healthcare Fund II L.P. | 3.1% | ||||
| Peter Harwin | 3.1% | ||||
| Kiselak Tomas | 3.1% | ||||
|
Viridian Therapeutics, Inc.\DE
13D/A
VRDN · 92790C104
|
14.0% |
5/13/2026
Event 5/11/2026
|
|||
| Fairmount Funds Management LLC | 14.0% | ||||
| Fairmount Healthcare Fund II GP LLC | 14.0% | ||||
|
Cogent Biosciences, Inc.
13D/A
COGT · 19240Q201
|
8.6% |
3/31/2026
Event 3/31/2026
|
|||
| Fairmount Funds Management LLC | 8.6% | ||||
| Fairmount Healthcare Fund II GP LLC | 8.6% | ||||
|
Inhibikase Therapeutics, Inc.
13G/A
IKT · 45719W205
|
9.9% |
2/17/2026
Event 12/31/2025
|
|||
| Fairmount Funds Management LLC | 9.9% | ||||
| Fairmount Healthcare Fund II L.P. | 9.9% | ||||
| Peter Harwin | 9.9% | ||||
| Tomas Kiselak | 9.9% | ||||
|
Galecto, Inc.
13D/A
DMRA · 36322Q206
|
20.0% |
2/11/2026
Event 2/9/2026
|
|||
| Fairmount Funds Management LLC | 20.0% | ||||
| Fairmount Healthcare Fund II L.P. | 13.3% | ||||
| Fairmount Healthcare Co-Invest V L.P. | 6.7% | ||||
| Peter Evan Harwin | 20.0% | ||||
| Tomas Kiselak | 20.0% | ||||
|
Dianthus Therapeutics, Inc.
13D/A
DNTH · 252828108
|
4.9% |
11/25/2025
Event 11/21/2025
|
|||
| Fairmount Funds Management LLC | 4.9% | ||||
| Fairmount Healthcare Fund II L.P. | 4.9% | ||||
| Peter Evan Harwin | 4.9% | ||||
| Tomas Kiselak | 4.9% | ||||
|
Astria Therapeutics, Inc.
13G/A
ATXS · 04635X102
|
4.0% |
10/15/2025
Event 10/14/2025
|
|||
| Fairmount Funds Management LLC | 4.0% | ||||
| Fairmount Healthcare Fund II GP LLC | 4.0% | ||||
|
Kiniksa Pharmaceuticals International, plc
13G/A
KNSA · G52694109
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Fairmount Funds Management LLC | 0% | ||||
| Fairmount Healthcare Fund II L.P. | 0% | ||||
| Peter Harwin | 0% | ||||
| Tomas Kiselak | 0% | ||||
|
Anaptysbio, Inc.
13G/A
ANAB · 032724106
|
0% |
2/14/2025
Event 12/31/2024
|
|||
| Fairmount Funds Management LLC | 0% | ||||
| Fairmount Healthcare Fund II L.P. | 0% | ||||
| Peter Harwin | 0% | ||||
| Tomas Kiselak | 0% | ||||